Road to PD0325901 and beyond: The MEK Inhibitor Quest

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 203-227

  Sebolt Leopold, Judith S ^a   Bridges, Alexander J ^a  

^a Oncovera Therapeutics   (United States)

Author keywords

CI 1040 and lessons learnt; RAS RAF MEK ERK signaling module and dysregulated RAS signaling; Road to PD0325901 and beyond MEK inhibitor quest

Indexed keywords

EID: 84889778596     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch8     Document Type: Chapter

References (27)

1. Adjei, A. A., Cohen, R. B., Franklin, W. A., et al. (2006). Phase I pharmacokinetic and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886). Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
2. Alessi, D. R., Cuenda, A., Cohen, P., et al. (1995). PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 270, 27489-27494.
3. Chow, L. Q. M., Eckhardt, S. G., Reid, J. M., et al. (2005). A first in human dose-range finding study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the MEK inhibitor, ARRY-142886 (AZD6244) in patients with advanced solid malignancies. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
4. Davies, H., Bignell, G. R., Cox, C., et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
5. Delaney, A. M., Printen, J. A., Chen, H., et al. (2002). Identification of a novel mitogen -activated protein kinase kinase activation domain recognized by the inhibitor PD184352. Mol Cell Biol. 22, 7593-7602.
6. Downward, J. (2003). Targeting ras signaling pathways in cancer therapy. Nat Rev Cancer. 3, 11-22.
7. Dudley, D. T., Pang, L., Decker, S. J., et al. (1995). A synthetic inhibitor of the mitogen -activated protein kinase cascade. Proc Natl Acad Sci USA. 92, 7686-7689.
8. Eliceiri, B. P., Klemke, R., Stromblad, S., et al. (1998). Integrin α v β 3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 141, 1255-1263.
9. Favata, M. F., Horiuchi, K. Y., Manos, E. J., et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 273 (9), 18623-18632.
10. Finlay, D., Healy, V., Furlong, F., et al. (2000). MAP kinase pathway signaling is essential for extracellular matrix determined mammary epithelial cell survival. Cell Death Differ. 7, 302-313.
11. Holmstrom, T. H., Tran, S. E., Johnson, V. L., et al. (1999). Inhibition of mitogen -activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 19, 5991-6002.
12. LoRusso, P., Adjei A., Varterasian, M., et al. (2005a). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 23 (23), 5281-5293.
13. LoRusso, P. A., Krishnamurthi, S., Rinehart J. J., et al. (2005b). A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol. [abstr] 23, 3006.
14. LoRusso, P. A., Krishnamurthi, S. S., Rinehart, J. J., et al. (2007). Clinical aspects of a Phase I study of PD-0325901,a selective oral MEK inhibitor, in patients with advanced cancer. Mol Cancer Ther. 6, 3649s [abstr B113].
15. Milanini, J., Vinals, F., Pouyssegur, J., et al. (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem. 273, 18165-18172.
16. Ohren, J. F., Chen, H., Pavlovsky, A., et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 11, 1192-1197.
17. Pages, G., Lenormand, D., L'Allemain, G., et al. (1993). Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA. 90, 8319-8323.
18. Pang, L., Sawada, T., Decker, S. J., et al. (1995). Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem. 270, 13585-13588.
19. Rinehart, J., Adjei, A. A., LoRusso, P. M., et al. (2004). Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 22 (22), 4456-4462.
20. Roberts, P. J., and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26, 3291-3310.
21. Sebolt-Leopold, J. S. (2008). Advances in the development of therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res. 14 (12), 3651-3656.
22. Sebolt-Leopold, J. S., and Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 4, 937-947.
23. Sebolt-Leopold, J. S., Dudley D. T., Herrera, R., et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 5, 810-816.
24. Sebolt-Leopold, J. S., Van Becelaere, K., Hook, K., et al. (2003). Biomarker assays for phosphorylated MAP kinase. Methods Mol Med. 85, 31-38.
25. Solit, D. B., Garraway, L. A., Pratilas, C. A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
26. Solit, D. B., Santos, E., Pratilas, C. A., et al. (2007). 3 ′-Deoxy-3 ′-[ 18 F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res. 67 (23), 11463-11469.
27. Tan, W., DePrimo, S., Krishnamurthi, S. S., et al. (2007), Pharmacokinetic (PK) and pharmacodynamic (PD) results of a Phase I study of PD-0325901, a second generation oral MEK inhibitor, in patients with advanced cancer. Mol Cancer Ther. 6, 3648s [abstr B109].